Nykredit A S Invests $205.77 Million in Pfizer Inc. $PFE

Key Points

• Nykredit A S acquired 8.55 million Pfizer shares worth approximately $205.8 million during the second quarter, representing a 0.15% stake. Institutional investors collectively own 68.36% of Pfizer.
• Pfizer reported quarterly EPS of $0.77 and revenue of $15.03 billion, exceeding analyst expectations, while maintaining 2026 EPS guidance of $2.80–$3.00.
• Analysts maintain a consensus “Hold” rating with an average price target of $28.28. Pfizer’s $0.43 quarterly dividend equates to a 5.9% annualized yield, though its payout ratio remains elevated at 226.32%.

Nykredit A S bought a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,545,428 shares of the biopharmaceutical company's stock, valued at approximately $205,774,000. Nykredit A S owned 0.15% of Pfizer as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. MBA Advisors LLC raised its holdings in Pfizer by 2.8% in the 2nd quarter. MBA Advisors LLC now owns 22,463 shares of the biopharmaceutical company's stock worth $541,000 after purchasing an additional 608 shares in the last quarter. Natural Investments LLC grew its holdings in shares of Pfizer by 117.3% during the 2nd quarter. Natural Investments LLC now owns 18,680 shares of the biopharmaceutical company's stock worth $449,000 after acquiring an additional 10,084 shares during the period. Beacon Financial Advisory LLC grew its holdings in shares of Pfizer by 1.5% during the 2nd quarter. Beacon Financial Advisory LLC now owns 49,663 shares of the biopharmaceutical company's stock worth $1,196,000 after acquiring an additional 722 shares during the period. Symphony Financial Ltd. Co. lifted its stake in shares of Pfizer by 9.0% in the 2nd quarter. Symphony Financial Ltd. Co. now owns 40,314 shares of the biopharmaceutical company's stock valued at $980,000 after purchasing an additional 3,334 shares during the period. Finally, Nan Shan Life Insurance Co. Ltd. boosted its position in shares of Pfizer by 7.7% during the second quarter. Nan Shan Life Insurance Co. Ltd. now owns 3,306,108 shares of the biopharmaceutical company's stock valued at $79,611,000 after purchasing an additional 235,799 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Guggenheim decreased their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a research note on Friday, August 7th. JPMorgan Chase & Co. decreased their price target on Pfizer from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Wednesday, July 8th. BMO Capital Markets lowered their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Finally, Wolfe Research reissued an "underperform" rating and issued a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Hold" and an average target price of $28.28.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

Pfizer Price Performance

NYSE PFE opened at $29.02 on Thursday. The business's fifty day moving average is $25.79 and its 200 day moving average is $26.32. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $29.09. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market capitalization of $165.42 billion, a PE ratio of 38.19, a price-to-earnings-growth ratio of 1.92 and a beta of 0.34.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter last year, the company earned $0.78 earnings per share. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 5.9%. Pfizer's payout ratio is currently 226.32%.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source